Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Clackson

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2005
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned ratsLaura M Sanftner, Victor M Rivera, Brian M Suzuki, et al.
Blood|October 28, 2004
Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transferVictor M Rivera, Guang-ping Gao, Rebecca L Grant, et al.
Blood|October 18, 2003
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate modelCarolina Berger, C Anthony Blau, Meei-Li Huang, et al.
Chemical Biology & Drug Design|December 24, 2009
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistanceMohammad Azam, John T Powers, William Einhorn, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Molecular Cancer Therapeutics|January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsJoseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Chemical Biology & Drug Design|December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistanceTianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
The EMBO Journal|May 1, 2002
JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cellsShengming Zhao, Karen Zoller, Masayoshi Masuko, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Pharmacologically regulated regeneration of functional human pancreatic isletsGary P Kobinger, Shaoping Deng, Jean-Pierre Louboutin, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2005
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned ratsLaura M Sanftner, Victor M Rivera, Brian M Suzuki, et al.
Blood|October 28, 2004
Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transferVictor M Rivera, Guang-ping Gao, Rebecca L Grant, et al.
Blood|October 18, 2003
Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate modelCarolina Berger, C Anthony Blau, Meei-Li Huang, et al.
Chemical Biology & Drug Design|December 24, 2009
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistanceMohammad Azam, John T Powers, William Einhorn, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Molecular Cancer Therapeutics|January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsJoseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Chemical Biology & Drug Design|December 2, 2010
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistanceTianjun Zhou, Lois Commodore, Wei-Sheng Huang, et al.
The EMBO Journal|May 1, 2002
JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cellsShengming Zhao, Karen Zoller, Masayoshi Masuko, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Pharmacologically regulated regeneration of functional human pancreatic isletsGary P Kobinger, Shaoping Deng, Jean-Pierre Louboutin, et al.
Pageof 6